Gossamer Bio, Inc.

As of June 30, 2026, Gossamer Bio, Inc. carries a market capitalization of 72.35M, placing it among publicly traded companies globally. Its enterprise value stands at 57.51M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Gossamer Bio, Inc.'s next confirmed earnings release is scheduled for November 5, 2026.

As of June 30, 2026, Gossamer Bio, Inc. has 6.11M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 0.80, and the price-to-book ratio stands at -0.88.

These figures are as of June 30, 2026. The EV/Sales ratio of 1.23 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 57.51M versus a market cap of 72.35M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Gossamer Bio, Inc. maintains a current ratio of 0.53, meaning it holds 0.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -42.61, indicating conservative leverage, while an interest coverage ratio of -15.07 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended June 30, 2026. Return on assets (ROA) is negative at -78.81, reflecting losses generated across the asset base. The company generates approximately 295,665.52 in revenue per employee across its workforce of 157.75, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, Gossamer Bio, Inc. recorded an income tax benefit of -77,026.40 rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -109.68M and -109.61M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on September 9, 2026, Gossamer Bio, Inc.'s stock has declined approximately 94.21% over the past 52 weeks. The 50-day moving average sits at 0.15, while the 200-day moving average is 0.90.

Over the twelve months ended June 30, 2026, Gossamer Bio, Inc. generated 46.64M in revenue and converted that into -109.61M in net income, yielding earnings per share of -34.47. EBITDA reached -144.57M, while operating income came in at -138.84M.

As of June 30, 2026, Gossamer Bio, Inc. holds 49.91M in cash and equivalents against 35.07M in total debt, resulting in a net debt position of -4.38M. Total book value stands at -82.30M, with working capital of -56.95M providing operational flexibility.

Gossamer Bio, Inc. produced -142.35M in operating cash flow over the twelve months ended June 30, 2026. After subtracting - - in capital expenditures, free cash flow totaled -142.35M - equivalent to -45.16 per share.

These figures cover the twelve months ended June 30, 2026. The operating margin of -297.67 and net profit margin of -235.00 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -378.10: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -3.87, meaning Gossamer Bio, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Gossamer Bio, Inc.'s most recent stock split took place on September 11, 2026 with a 80:1 split ratio.

As of June 30, 2026, Gossamer Bio, Inc. has an Altman Z-Score of -33.59, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.